Tolerability aspects in duloxetine-treated patients with depression: should one use a lower starting dose in clinical practice?
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Expert opinion on drug safety - 11(2012), 5 vom: Sept., Seite 699-712 |
| Beteiligte Personen: |
Wilhelm, Stefan [VerfasserIn] |
|---|
| BKL: |
|---|
| Umfang: |
13 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1901941566 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC1901941566 | ||
| 003 | DE-627 | ||
| 005 | 20230509185043.0 | ||
| 007 | tu | ||
| 008 | 120824s2012 xx ||||| 00| ||und c | ||
| 028 | 5 | 2 | |a sw120823_1 |
| 035 | |a (DE-627)OLC1901941566 | ||
| 035 | |a (DE-599)GBVOLC1901941566 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 082 | 0 | 4 | |a 610 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Wilhelm, Stefan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tolerability aspects in duloxetine-treated patients with depression: should one use a lower starting dose in clinical practice? |
| 264 | 1 | |c 2012 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 700 | 1 | |a Boess, Frank G |4 oth | |
| 700 | 1 | |a Hegerl, Ulrich |4 oth | |
| 700 | 1 | |a Mergl, Roland |4 oth | |
| 700 | 1 | |a Linden, Michael |4 oth | |
| 700 | 1 | |a Schacht, Alexander |4 oth | |
| 700 | 1 | |a Schneider, Edith |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug safety |d London : Informa Healthcare, 2002 |g 11(2012), 5 vom: Sept., Seite 699-712 |w (DE-627)354542478 |w (DE-600)2088728-0 |w (DE-576)435515020 |x 1474-0338 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2012 |g number:5 |g month:09 |g pages:699-712 |g extent:13 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 11 |j 2012 |e 5 |c 9 |h 699-712 |g 13 | ||